Cargando…

The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids

Chronic rhinosinusitis (CRS) is a chronic inflammatory disease phenotypically classified by the absence (CRSsNP) or presence of nasal polyps (CRSwNP). The latter may also be associated with asthma and hypersensitivity towards non-steroidal anti-inflammatory drugs (NSAID) as a triad termed NSAID-exac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartosik, Tina J., Campion, Nicholas J., Freisl, Kilian, Liu, David T., Gangl, Katharina, Stanek, Victoria, Tu, Aldine, Pjevac, Petra, Hausmann, Bela, Eckl-Dorna, Julia, Schneider, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140405/
https://www.ncbi.nlm.nih.gov/pubmed/37122714
http://dx.doi.org/10.3389/fimmu.2023.1112345
_version_ 1785033152718176256
author Bartosik, Tina J.
Campion, Nicholas J.
Freisl, Kilian
Liu, David T.
Gangl, Katharina
Stanek, Victoria
Tu, Aldine
Pjevac, Petra
Hausmann, Bela
Eckl-Dorna, Julia
Schneider, Sven
author_facet Bartosik, Tina J.
Campion, Nicholas J.
Freisl, Kilian
Liu, David T.
Gangl, Katharina
Stanek, Victoria
Tu, Aldine
Pjevac, Petra
Hausmann, Bela
Eckl-Dorna, Julia
Schneider, Sven
author_sort Bartosik, Tina J.
collection PubMed
description Chronic rhinosinusitis (CRS) is a chronic inflammatory disease phenotypically classified by the absence (CRSsNP) or presence of nasal polyps (CRSwNP). The latter may also be associated with asthma and hypersensitivity towards non-steroidal anti-inflammatory drugs (NSAID) as a triad termed NSAID-exacerbated respiratory disease (N-ERD). The role of the microbiome in these different disease entities with regard to the underlying inflammatory process and disease burden is yet not fully understood. To address this question, we measured clinical parameters and collected nasal samples (nasal mucosal fluids, microbiome swabs from middle meatus and anterior naris) of patients suffering from CRSsNP (n=20), CRSwNP (n=20) or N-ERD (n=20) as well as from patients without CRS (=disease controls, n=20). Importantly, all subjects refrained from taking local or systemic corticosteroids or immunosuppressants for at least two weeks prior to sampling. The nasal microbiome was analyzed using 16S rRNA gene amplicon sequencing, and levels of 33 inflammatory cytokines were determined in nasal mucosal fluids using the MSD platform. Patients suffering from N-ERD and CRSwNP showed significantly worse smell perception and significantly higher levels of type 2 associated cytokines IL-5, IL-9, Eotaxin and CCL17. Across all 4 patient groups, Corynebacteria and Staphylococci showed the highest relative abundances. Although no significant difference in alpha and beta diversity was observed between the control and the CRS groups, pairwise testing revealed a higher relative abundance of Staphylococci in the middle meatus in N-ERD patients as compared to CRSwNP (p<0.001), CRSsNP (p<0.01) and disease controls (p<0.05) and of Lawsonella in patients suffering from CRSwNP in middle meatus and anterior naris in comparison to CRSsNP (p<0.0001 for both locations) and disease controls (p<0.01 and p<0.0001). Furthermore, we observed a positive correlation of Staphylococci with IL-5 (Pearson r=0.548) and a negative correlation for Corynebacteria and Eotaxin-3 (r=-0.540). Thus, in patients refraining from oral and nasal corticosteroid therapy for at least two weeks known to alter microbiome composition, we did not observe differences in microbiome alpha or beta diversity between various CRS entities and disease controls. However, our data suggest a close association between increased bacterial colonization with Staphylococci and decreased colonization by Corynebacteria as well as increased type 2 inflammation.
format Online
Article
Text
id pubmed-10140405
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101404052023-04-29 The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids Bartosik, Tina J. Campion, Nicholas J. Freisl, Kilian Liu, David T. Gangl, Katharina Stanek, Victoria Tu, Aldine Pjevac, Petra Hausmann, Bela Eckl-Dorna, Julia Schneider, Sven Front Immunol Immunology Chronic rhinosinusitis (CRS) is a chronic inflammatory disease phenotypically classified by the absence (CRSsNP) or presence of nasal polyps (CRSwNP). The latter may also be associated with asthma and hypersensitivity towards non-steroidal anti-inflammatory drugs (NSAID) as a triad termed NSAID-exacerbated respiratory disease (N-ERD). The role of the microbiome in these different disease entities with regard to the underlying inflammatory process and disease burden is yet not fully understood. To address this question, we measured clinical parameters and collected nasal samples (nasal mucosal fluids, microbiome swabs from middle meatus and anterior naris) of patients suffering from CRSsNP (n=20), CRSwNP (n=20) or N-ERD (n=20) as well as from patients without CRS (=disease controls, n=20). Importantly, all subjects refrained from taking local or systemic corticosteroids or immunosuppressants for at least two weeks prior to sampling. The nasal microbiome was analyzed using 16S rRNA gene amplicon sequencing, and levels of 33 inflammatory cytokines were determined in nasal mucosal fluids using the MSD platform. Patients suffering from N-ERD and CRSwNP showed significantly worse smell perception and significantly higher levels of type 2 associated cytokines IL-5, IL-9, Eotaxin and CCL17. Across all 4 patient groups, Corynebacteria and Staphylococci showed the highest relative abundances. Although no significant difference in alpha and beta diversity was observed between the control and the CRS groups, pairwise testing revealed a higher relative abundance of Staphylococci in the middle meatus in N-ERD patients as compared to CRSwNP (p<0.001), CRSsNP (p<0.01) and disease controls (p<0.05) and of Lawsonella in patients suffering from CRSwNP in middle meatus and anterior naris in comparison to CRSsNP (p<0.0001 for both locations) and disease controls (p<0.01 and p<0.0001). Furthermore, we observed a positive correlation of Staphylococci with IL-5 (Pearson r=0.548) and a negative correlation for Corynebacteria and Eotaxin-3 (r=-0.540). Thus, in patients refraining from oral and nasal corticosteroid therapy for at least two weeks known to alter microbiome composition, we did not observe differences in microbiome alpha or beta diversity between various CRS entities and disease controls. However, our data suggest a close association between increased bacterial colonization with Staphylococci and decreased colonization by Corynebacteria as well as increased type 2 inflammation. Frontiers Media S.A. 2023-04-14 /pmc/articles/PMC10140405/ /pubmed/37122714 http://dx.doi.org/10.3389/fimmu.2023.1112345 Text en Copyright © 2023 Bartosik, Campion, Freisl, Liu, Gangl, Stanek, Tu, Pjevac, Hausmann, Eckl-Dorna and Schneider https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bartosik, Tina J.
Campion, Nicholas J.
Freisl, Kilian
Liu, David T.
Gangl, Katharina
Stanek, Victoria
Tu, Aldine
Pjevac, Petra
Hausmann, Bela
Eckl-Dorna, Julia
Schneider, Sven
The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title_full The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title_fullStr The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title_full_unstemmed The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title_short The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
title_sort nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140405/
https://www.ncbi.nlm.nih.gov/pubmed/37122714
http://dx.doi.org/10.3389/fimmu.2023.1112345
work_keys_str_mv AT bartosiktinaj thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT campionnicholasj thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT freislkilian thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT liudavidt thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT ganglkatharina thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT stanekvictoria thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT tualdine thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT pjevacpetra thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT hausmannbela thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT eckldornajulia thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT schneidersven thenasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT bartosiktinaj nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT campionnicholasj nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT freislkilian nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT liudavidt nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT ganglkatharina nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT stanekvictoria nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT tualdine nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT pjevacpetra nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT hausmannbela nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT eckldornajulia nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids
AT schneidersven nasalmicrobiomeinpatientssufferingfromnonsteroidalantiinflammatorydrugsexacerbatedrespiratorydiseaseinabsenceofcorticosteroids